Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.77 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.77 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.77 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.77 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.77 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.77 |
| ▸ | PLAU | P00749 | 3/20 | 0.63 |
| ▸ | PLG | P00747 | 2/20 | 0.57 |
| ▸ | F10 | P00742 | 1/20 | 0.57 |
| ▸ | PLAT | P00750 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311708 | 0.91 | F2 (0.65) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL13791589 | 0.86 | PLAU (0.71) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL4224686 | 0.85 | F2 (0.74) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL13714709 | 0.84 | F2 (0.61) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL30583351 | 0.83 | PLAU (0.63) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL14599554 | 0.83 | PRSS1 (0.71) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL7903320 | 0.83 | F2 (0.71) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL8994029 | 0.83 | F2 (0.71) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL12348110 | 0.82 | F7 (0.67) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| SCHEMBL4426386 | 0.82 | F7 (0.64) | F2PRSS1PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932300-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | NSUN2, EIF2AK2, RNGTT | F2 4809/4885PRSS1 1796/4885PRSS2 2174/4885 |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | NSUN2, EIF2AK2, RNGTT | F2 4809/4885PRSS1 1796/4885PRSS2 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.